| Literature DB >> 24244637 |
Laurence M Renard1, Valery Bocquet, Gwenaelle Vidal-Trecan, Marie-Lise Lair, Claudine Blum-Boisgard.
Abstract
INTRODUCTION: Type 2 diabetes is associated with severe micro- and macro-vascular complications. Physicians' and patients' adherence to follow-up guidelines permits postponing or reducing these complications. The objectives were to assess the level of adherence to fundamental follow-up guidelines and determine patients' characteristics associated with this level of adherence in the context of Luxembourg, where no guidelines were implemented. STUDY POPULATION: The exhaustive residing population treated for type 2 diabetes in Luxembourg during the 2000-2006 period (N = 21,068).Entities:
Mesh:
Substances:
Year: 2013 PMID: 24244637 PMCID: PMC3823868 DOI: 10.1371/journal.pone.0080162
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Descriptive statistics of the study population.
| Category | Subcategory | 2000 | 2003 | 2006 |
| Patients (number) | 13152 | 15269 | 17070 | |
| Male (%) | 50.9 | 52.1 | 53.2 | |
| Median age (y) | 64.6 | 64.9 | 65.2 | |
| Luxembourg nationality (%) | 77.4 | 74.8 | 72.0 | |
| Regional repartition (%) | Luxembourg | 72.8 | 73.6 | 73.6 |
| Grevenmacher | 15.6 | 15.0 | 15.1 | |
| Diekirch | 11.6 | 11.4 | 11.3 | |
| Treatment repartition (%) | Solely oral hypoglycemic agent | 75.8 | 76.8 | 77.0 |
| Solely insulin | 9.9 | 9.7 | 9.7 | |
| Mixed treatment | 10.3 | 9.5 | 10.6 | |
| Unknown | 4.0 | 4.0 | 2.7 |
List of the 7 fundamental criteria for type 2 diabetes follow-up.
| Criterion | Name | Frequency | Definition |
|
| Consultation with the patient’s treating physician or diabetologist | 4/year |
|
|
| |||
|
| HbA1c Test | 4/year | All tests blocks including glycosylated hemoglobin test |
|
| Retinal check-up | 1/year | One |
|
| Dental check-up | 1/year | One |
|
| Lipid check-up | 1/year | One |
|
| Renal check-up | 1/year | One |
|
| Electrocardiogram (ECG) | 1/year | All excluding monitoring ECG during an intervention |
Figure 1Radar chart of the adherence to criteria 2 to 7 in 2000, 2003 and 2006 (% of patients) and evolution between 2000 and 2006 (points).
Level of adherence according to the number of criteria achieved each year (% of patients).
| Level of adherence | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 |
|
| 21.7 | 20.2 | 19.4 | 18.3 | 15.1 | 15.7 | 15.0 |
|
| 35.1 | 33.9 | 31.8 | 29.9 | 24.1 | 25.6 | 23.4 |
|
| 27.2 | 27.9 | 27.2 | 28.4 | 25.4 | 27.0 | 25.2 |
|
| 12.0 | 13.2 | 14.8 | 16.1 | 20.2 | 18.8 | 20.4 |
|
| 3.2 | 3.9 | 5.3 | 5.6 | 11.3 | 9.7 | 11.6 |
|
| 0.8 | 0.8 | 1.3 | 1.6 | 3.5 | 2.9 | 3.8 |
|
| 0.1 | 0.2 | 0.2 | 0.2 | 0.4 | 0.3 | 0.6 |
|
| 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
Odds ratios [95%CI] from cumulative odds models of adherence to guidelines (from 0: any adherence to 6: full adherence) between 2000 and 2006.
| 2003 | 2006 | ||||||||
| N | OR [95% CI] | N | OR [95% CI] | ||||||
| 6 vs others | 3,4,5,6 vs others | 1,2,3,4,5,6 vs 0 | 6 vs others | 3,4,5,6 vs others | 1,2,3,4,5,6 vs 0 | ||||
|
| 14659 | 1.10 [0.94−1.29] |
| 0.99 [0.97−1.00] | 16602 | 0.99 [0.99−1.00] |
|
| |
|
| 14659 | 1.01 [0.98−1.05] |
|
| 16602 |
| 0.99 [0.98−1.01] |
| |
|
| 14659 | 1.02 [1.00−1.03] |
|
| 16602 |
|
|
| |
|
| Female | 7049 | 1 | 1 | 1 | 7718 | 1 | 1 | 1 |
| Male | 7610 | 0.59 [0.26−1.37] |
|
| 8884 |
|
|
| |
|
| D c | 1230 | 1 | 1 | 1 | 1422 | 1 | 1 | 1 |
| I-D c | 3416 |
|
| 0.83 [0.68−1.02] | 4100 | 0.75 [0.42−1.32] |
|
| |
| G-ID c | 9314 |
|
|
| 10423 |
|
|
| |
| O-GID c | 699 | 0.12 [0.01−1.18] |
|
| 657 | 0.18 [0.03−1.10] |
|
| |
|
| Luxembourg | 10719 | 1 | 1 | 1 | 12169 | 1 | 1 | 1 |
| Grevenmacher | 1677 |
|
|
| 1891 | 1.65 [0.96−2.85] |
|
| |
| Diekirch | 2263 |
|
|
| 2542 | 1.39 [0.80−2.40] |
|
| |
|
| Luxembourg | 11053 | 1 | 1 | 1 | 12094 | 1 | 1 | 1 |
| EU-15 and EFTA d | 3189 | 0.75 [0.26−2.18] | 0.94 [0.86−1.04] | 0.95 [0.86−1.06] | 3971 | 0.65 [0.37−1.13] | 0.99 [0.92−1.07] | 0.94 [0.85−1.04] | |
| Other | 417 | 0.40 [0.01−23.62] |
|
| 537 | 0.41 [0.07−2.44] |
|
| |
|
| Insulin only | 1484 | 1 | 1 | 1 | 1658 | 1 | 1 | 1 |
| Oral only | 11727 |
|
|
| 13142 |
|
|
| |
| Mixed | 1448 |
|
|
| 1802 |
|
|
| |
|
| None | 4215 | 1 | 1 | 1 | 5426 | 1 | 1 | 1 |
|
| n-2 or earlier | 0 | NA | NA | NA | 6062 |
|
|
|
| n-1 or n | 4168 | 2.09 [0.53−8.23] |
| 1.08 [0.96−1.21] | 5114 |
|
|
| |
| n+1 or later | 6276 | 1.65 [0.41−6.70] |
|
| 0 | NA | NA | NA | |
A10 treatment duration; b Number of visits to the Treating Physician (TP); c D: At least a diabetologist; I-D: At least an internist but no diabetologist; G-ID: At least a GP but no diabetologist, nor internist; O-GID: A physician but no GP, nor diabetologist, nor internist; d European Union 15 countries (except Luxembourg) and European Free Trade Association countries; NA: Not available.